|Day Low/High||8.77 / 9.75|
|52 Wk Low/High||5.00 / 10.00|
Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity
Topline Data Expected in the First Half of 2018
Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity
Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018
Company to pursue up-listing to a major stock exchange in 2017
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal
SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million
Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board
Listing Offers Product Exclusivity Until 2035
Approval Granted as Canada Confronts Opioid Crisis
Board Appointments Reflect Opiant's Development as a Commercial-Stage Pharmaceutical Company
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of OPNET Technologies Inc.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of OPNET Technologies, Inc.
Ryan & Maniskas, LLP ( www.rmclasslaw.